Financial Performance - The group's revenue increased by 2.6% from RMB 1,369.5 million for the year ended December 31, 2023, to RMB 1,405.5 million for the year ended December 31, 2024[2]. - The group's profit before tax decreased by 12.2% from RMB 299.2 million to RMB 262.7 million, with a profit before tax margin dropping from 21.9% to 18.7%[2]. - The group's net profit fell by 15.6% from RMB 220.7 million to RMB 186.2 million, resulting in a net profit margin decline from 16.1% to 13.2%[3]. - The adjusted net profit under non-IFRS decreased by 9.1% from RMB 223.1 million to RMB 202.7 million, with the adjusted net profit margin dropping from 16.3% to 14.4%[3]. - The group's gross profit margin decreased from 45.4% to 43.5%[7]. - The group's EBITDA under non-IFRS was RMB 374.1 million, slightly down from RMB 377.3 million in the previous year[7]. - The total gross profit for the group was RMB 611.3 million, a decrease of 1.6% from RMB 621.1 million in the previous year[18]. - The company's net asset value was RMB 2,326,151 thousand, down from RMB 2,378,425 thousand in 2023, reflecting a decrease of 2.2%[96]. - The company reported a significant increase in cash and cash equivalents, reaching RMB 780,785 thousand, compared to RMB 463,437 thousand in 2023, an increase of 68.4%[95]. Revenue Sources - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[14]. - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, serving as another major revenue source[17]. - Revenue from consumer ophthalmology services decreased by 0.4% from RMB 709.2 million to RMB 706.4 million, indicating a slowdown in the Chinese consumer market[30]. - Revenue from basic ophthalmology services increased by 6.7% from RMB 654.0 million to RMB 697.8 million, driven by enhanced marketing activities and improved patient conversion rates[31]. Operational Metrics - Outpatient visits increased to 1,137,742 in 2024 from 1,128,719 in 2023, with an average spending per visit rising from RMB 698 to RMB 713[9]. - Inpatient visits rose to 72,120 in 2024 from 67,258 in 2023, while average spending per inpatient visit decreased from RMB 7,109 to RMB 6,914[9]. - The optical center recorded 105,354 customer visits in 2024, down from 120,184 in 2023, with average sales price increasing from RMB 806 to RMB 900[9]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.1193 per share for the year ended December 31, 2024, down from HKD 0.2208 per share in 2023[4]. - The total interim dividend declared and paid for the six months ended June 30, 2024, was approximately HKD 90.28 million (equivalent to RMB 82.5 million)[4]. - The company has declared a final dividend of HKD 0.2208 per share and a special dividend of HKD 0.0767 per share, totaling approximately HKD 205.5 million (approximately RMB 187.1 million) for the year ended December 31, 2023[88]. Employee and Operational Structure - As of December 31, 2024, the group employed a total of 1,464 full-time medical professionals, including 296 doctors, 625 nurses, and 543 other professionals[20]. - The company has 267 registered full-time ophthalmologists as of December 31, 2024, contributing to its medical expertise[79]. - The total employee benefit expenses increased to RMB 421,240 in 2024 from RMB 377,754 in 2023, reflecting a growth of 11.5%[115]. - Employee compensation includes basic salary, performance-related bonuses, and discretionary year-end bonuses, with regular performance evaluations for salary reviews[80]. Strategic Initiatives and Future Plans - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[26]. - The company plans to invest HKD 200 million in research and development for innovative eye care solutions over the next two years[132]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs by optimizing supply chain management[132]. - Future guidance indicates a potential revenue growth of 10-15% annually over the next three years[132]. Financial Position and Liabilities - The total liabilities decreased to RMB 554,765 thousand from RMB 544,381 thousand in 2023, indicating a slight increase in financial obligations[96]. - The total interest-bearing borrowings as of December 31, 2024, amounted to RMB 40,629,000, compared to RMB 7,153,000 in 2023, showing a significant increase[126]. - Trade receivables increased by 33.6% from RMB 55.7 million for the year ended December 31, 2023, to RMB 74.4 million for the year ending December 31, 2024, due to growth in basic ophthalmic services[45]. Compliance and Governance - The company has confirmed compliance with corporate governance codes and standards since January 1, 2024[67]. - The audit committee and independent auditors confirmed that the annual performance for the year ending December 31, 2024, complies with applicable accounting standards and regulations[84]. - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[70].
朝聚眼科(02219) - 2024 - 年度业绩